Accenture and 1910 Genetics Unite to Revolutionize Drug Discovery with AI-Driven Solutions

Accenture and 1910 Genetics Unite to Revolutionize Drug Discovery with AI-Driven Solutions

(IN BRIEF) Accenture has invested in 1910 Genetics, a biotech firm leveraging AI-driven lab automation to enhance drug discovery for small and large molecule therapies. This partnership aims to provide biopharma clients with a powerful AI platform, streamlining the drug discovery process, reducing costs, and improving patient outcomes. The collaboration combines Accenture’s AI and enterprise scalability expertise with 1910’s comprehensive Input-Transform-Output (ITO™) platform, which facilitates precise target identification and accelerates drug development across various therapeutic areas. Key figures from both companies will join advisory boards, and 1910 will join Accenture Ventures’ Project Spotlight for emerging technologies.

(PRESS RELEASE) DUBLIN, 1-Nov-2024 — /EuropaWire/ — Accenture (NYSE: ACN) has strategically invested in 1910 Genetics, a biotechnology firm pioneering small and large molecule drug discovery through its advanced multimodal AI platform, powered by laboratory automation. This press release was authored by Accenture, highlighting a partnership that aims to leverage Accenture’s AI expertise and scalable infrastructure with 1910’s unique technology to accelerate the drug discovery process, reduce costs, and improve patient outcomes for biopharma clients.

At the core of 1910 Genetics’ approach is its Input-Transform-Output (ITO™) platform, a powerful, end-to-end AI system that supports drug discovery across a range of therapeutic areas. This platform integrates hundreds of AI models and employs federated learning, combining computational data, wet lab ground-truth biological data, and wet lab proxy biological data to streamline high-precision target identification and optimize molecule design throughout the R&D process. Designed to accelerate clinical success, the platform enhances data-driven decision-making, shortens experimental cycles, and lowers drug development costs.

Tom Lounibos, global lead of Accenture Ventures, emphasized the importance of AI in reimagining drug discovery. “Our collaboration with 1910 Genetics allows us to merge our AI capabilities with their innovative platform, delivering solutions that can revolutionize drug discovery and enhance patient care,” he said.

Accenture’s strengths in deploying AI solutions at an enterprise level will help biopharma companies integrate 1910’s platform seamlessly into existing workflows. Together, the two organizations aim to drive innovation in drug discovery, improve efficiency, and deliver breakthroughs in therapeutic development.

Petra Jantzer, PhD, Accenture’s global lead for Life Sciences, expressed excitement about the partnership, stating, “Our extensive experience with generative AI and expertise in life sciences, combined with 1910 Genetics’ comprehensive AI platform, aligns perfectly with our vision to help biopharma clients transform R&D. By automating workflows, dismantling silos, and enhancing productivity, we support tech-enabled drug discovery.”

Founder and CEO of 1910 Genetics, Dr. Jen Nwankwo, emphasized the platform’s holistic design, noting, “Our AI platform provides an end-to-end solution that addresses common biopharma challenges with point solutions. Partnering with Accenture enables us to offer biopharma companies an enterprise-wide infrastructure that accelerates both small and large molecule therapeutic development.”

To further support collaboration, Accenture representatives Dr. Petra Jantzer and Tom Lounibos will join 1910’s Business Advisory Board, with Accenture’s Dr. Kailash Swarna and Dr. Cecil Lynch joining the Technology Advisory Board. Additionally, 1910 will become part of Accenture Ventures’ Project Spotlight, a program that fosters disruptive enterprise technology startups.

The investment terms were not disclosed.

About Accenture
Accenture is a leading global professional services company that helps the world’s leading organizations build their digital core, optimize their operations, accelerate revenue growth and enhance services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 774,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world’s leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. Our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at www.accenture.com.

About 1910 Genetics
1910 Genetics is the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. We integrate AI that leverages federated learning alongside three proprietary data streams—computational data, wet lab proxy biological data, and wet lab ground truth biological data—to deliver novel drug candidates and software solutions to leading biopharma and tech partners, and advance our internal pipeline for neurological, autoimmune diseases, and cancer. We recently established a commercial partnership with Microsoft to bring our ITO™ platform to biopharma companies at scale.

1910 was launched in 2021 with a combined seed and Series A funding of $26.1M from M12-Microsoft’s Venture Fund, Playground Global, OpenAI’s Sam Altman, FoundersX Ventures, and other leading investors. We have since established our HQ and lab facilities in Boston’s Seaport District and continue to hire a world-class team. To learn more, visit www.1910genetics.com.

Media Contacts:

Marchell Gillis
Accenture
+1 678 657 7515
marchell.gillis@accenture.com

Keerthi Goutham
Accenture
keerthi.goutham@accenture.com

1910 Genetics PR
media@1910Genetics.com

SOURCE: Accenture